SATSUMA PHARMACEUTICALS
Summary
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions. Our initial product candidate is STS101 (dihydroergotamine (DHE) nasal powder).
Deals Overview
Total Deals1
Valued Deals1
Total Value£ 177 M
Avg. Deal Size£ 177 M
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.
